Skip to main content

Table 3 Summary of diaphragm muscle parameters from experiment 2. Effect of 3 months of treatment with either vehicle or 30 ug/kg PG873637 on male 2-month-old (at time 0) mdx and C57BL10 mice.

From: Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice

 

Mdx time 0

Mdx Vehicle

Mdx PG-873637

C57BL10 time 0

C57BL10 vehicle

Number of animals

10

9

11

10

10

Initial body mass (g)

21.90 (0.64)

22.43 (0.67)

22.32 (0.97)

24.21 (0.71)

24.69 (0.45)

Final body mass (g)

21.90 (0.64)

29.79† (0.50)

31.19† (0.63)

24.21 (0.71)

30.35† (0.66)

Diaphragm mass (g)

0.0027 (0.0002)

0.0040† (0.0003)

0.0043† (0.0002)

0.0023 (0.0001)

0.0027 (0.0002)

Diaphragm sPo (kN/m2)

120.12 (7.35)

91.90† (7.06)

112.58* (5.21)

210.22 (9.51)

196.49 (8.69)

Diaphragm Po (mN)

45.19 (5.92)

49.73 (5.46)

60.36† (3.09)

59.10 (3.75)

57.86 (3.98)

Diaphragm Pt (mN)

13.43 (1.72)

13.99 (1.40)

16.72 (1.05)

15.40 (1.04)

20.03* (1.51)

Diaphragm HRT (ms)

65.65 (2.75)

67.31 (4.42)

62.52 (2.49)

85.56 (3.44)

90.69 (6.27)

Diaphragm TPT (ms)

39.21 (1.31)

38.15 (1.26)

37.80 (0.56)

40.00 (0.86)

39.99 (1.14)

  1. sPo, muscle specific force; Po, muscle absolute force; Pt, muscle peak twitch force; HRT, muscle half relaxation time; TPT, muscle time to peak tension. All data are given as the mean with standard error of the mean in parenthesis. *Statistically significant difference (p < 0.05) versus the appropriate vehicle control; † statistically significant difference (p < 0.05) versus time 0.